Roy Baynes, MB.Bch., M.Med., Ph.D., has served as a member of Nurix’s Medical Advisory Board since 2023. Dr. Baynes currently serves as Chief Medical Officer at Eikon Therapeutics, Inc. Dr. Baynes previously served as Chief Medical Officer at Merck & Co., where he was responsible for the development of the entire clinical portfolio in Merck Research Laboratories, and was the architect of the development strategy for dozens of important new medicines including pembrolizumab, a humanized monoclonal antibody used in cancer immunotherapy that treats some 17 different tumor types as well as two histology agnostic indications. Earlier in his career, Dr. Baynes served as Vice President of Global Development and head of the hematology/oncology development team at Amgen, Inc., as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., and as Professor of Medicine at University of Kansas Medical Center and Wayne State University in Detroit as well as holding the Charles Martin endowed chair of Cancer Research at Wayne State University. Dr. Baynes holds an MB.BCh. (Bachelor of Medicine and Surgery), an M.Med. (specialist registration in Internal Medicine), and a Ph.D. from the University of Witwatersrand.
Ronald Levy, M.D.
Ronald Levy, M.D., has served as a member of Nurix’s Medical Advisory Board since 2023. Dr. Levy is the Robert K. Summy and Helen K. Summy Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine. He is also the Associate Director of Translational Science for the Stanford Cancer Institute. For more than 25 years, Dr. Levy’s research has focused on monoclonal antibodies and the study of malignant lymphoma, currently using the tools of immunology and molecular biology to develop a better understanding of the initiation and progression of the malignant process. He was the first to successfully treat cancer with a monoclonal antibody, and went on to help develop rituximab, the first FDA-approved antibody for the treatment of lymphoma. Dr. Levy holds an A.B. in Biochemistry from Harvard University and an M.D. from Stanford University.
John Kuriyan, Ph.D.
John Kuriyan, Ph.D., is an expert in the structural dynamics of ubiquitin ligases and other signaling complexes. Dr. Kuriyan is a Howard Hughes Medical Institute Investigator and a Professor of Molecular and Cell Biology and of Chemistry, University of California, Berkeley. Prior to that, he served as Assistant Professor and then Professor at Rockefeller University for 14 years. Dr. Kuriyan serves as a member of the Advisory Board at Carmot Therapeutics Inc. and is a Senior Editor at eLife, a new enterprise in high profile and open access scientific publishing. He is a member of the National Academy of Sciences, which awarded him the 2005 Richard Lounsbery Award. He holds a B.S. in chemistry from Juniata College, Pennsylvania, and a Ph.D. from the Massachusetts Institute of Technology.
Michael Rapé, Ph.D.
Michael Rapé, Ph.D., is a leader in the biology of ubiquitin-dependent cell cycle progression and carcinogenesis. He is a Howard Hughes Investigator and a Professor of Cell and Developmental Biology at the University of California, Berkeley. He started his own lab at the University of California, Berkeley in the fall of 2006, where he has developed novel screening tools to identify the ubiquitylation enzymes that are important for cell division and differentiation and pair them with the proteins they target. Prior to that, he completed his postdoctoral research at Harvard Medical School in the lab of Marc Kirschner. In recognition of his creativity and productivity, Dr. Rapé was named a Pew Scholar and received the NIH Director’s New Innovator Award in 2007. He has also won prestigious fellowships from the Human Frontier Science Program and the European Molecular Biology Organization. Dr. Rapé studied Biochemistry at the University of Bayreuth in Germany and received his Ph.D. at the MPI in Martinsried, Germany in the lab of Stefan Jentsch.
Michael Roth, M.A.
Michael Roth has served as Vice President of Quality at Nurix since May 2024. Mr. Roth has over 30 years of pharmaceutical experience overseeing all aspects of quality assurance and compliance, as well as extensive experience managing PAI/BIMO inspections and commercial activities. Prior to joining Nurix, Mr. Roth served as Vice President of Quality Assurance at Rain Oncology, where he managed the quality groups and supported the company’s clinical and non-clinical studies. Previously, he served as Vice President of Quality Assurance at Principia Biopharma, Executive Director of Quality Assurance at Rigel Pharmaceuticals, and Director of Quality Control and Assurance at Zosano Pharma. He has collaborated on three drugs that received FDA approval. Mr. Roth holds a B.A. in Chemistry from the State University College of Buffalo and an M.A. in Pharmacology from the State University of New York at Buffalo (RPMI).
Marine Champsaur, Ph.D.
Marine Champsaur, Ph.D., has served as Vice President and Head of Medical Affairs since August 2022. Prior to joining Nurix, Dr. Champsaur provided scientific strategy and communications consulting services to early-stage biotech companies across a range of treatment modalities spanning the autoimmune and inflammatory disease, vaccine, and oncology space. Before that, Dr. Champsaur played a pivotal role in building the medical affairs function at Dermira, Inc., where she led the medical strategy and communications team. Early in her career, she held roles of increasing responsibility at UCB Pharma within immunology global medical affairs. Dr. Champsaur holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley, and a Ph.D. in Immunology from the University of California, San Francisco.
Linda L. Neuman, M.D., M.B.A.
Linda L. Neuman, M.D., M.B.A., has served as Vice President of Clinical Development at Nurix since May 2024. Dr. Neuman is trained as an internist, practiced medicine for 10 years prior to entering industry, and has more than 12 years of drug development experience in both oncology and rare disease. Prior to joining Nurix, she held senior positions in clinical development at Aeglea BioTherapeutics, Catalyst Biosciences, Adverum Biotechnologies, Sunesis Pharmaceuticals, Puma Biotechnology, and Onyx Pharmaceuticals. Dr. Neuman completed her internal medicine residency at St. Vincent’s Hospital in Indianapolis. She holds a B.S. in Biology from Southern Illinois University at Edwardsville, an M.B.A from Indiana Wesleyan University, and an M.D from Southern Illinois University.
Joseph D. Robinson
Joseph D. Robinson has served as Vice President, Facilities Operations at Nurix since July 2023. Mr. Robinson has been responsible for developing the facilities, real estate, lab services and operations functions at Nurix since he joined the company in January 2016. Prior to Nurix, Mr. Robinson served in positions of increasing responsibility developing and growing administrative and operational functions for early-stage companies, including Presidio Pharmaceuticals, a developer of anti-viral therapeutics, and VaxGen, a vaccine company. Mr. Robinson began his career at the Conant Medical Group. Mr. Robinson studied Communications at San Francisco State University and Management at St. Mary’s College of California.
Eva Kras
Eva Kras, M.S., joined Nurix in 2023 and has served as Vice President and Head of Regulatory Affairs since February 2024. Ms. Kras has over 22 years of experience in drug development, spanning early to late-stage programs across several therapeutic areas, including oncology/hematology and rare disease. Throughout her career, she has been responsible for developing innovative regulatory strategies leading to numerous global regulatory marketing approvals. Prior to joining Nurix, she held a variety of roles at Amgen, Seattle Genetics, BioMarin, GSK, Coherus and most recently BeiGene. Ms. Kras earned her B.S. in Pharmacology from the University of California, Santa Barbara, and her M.S. in Regulatory Science from the USC School of Pharmacy.
Eren Demirhan, Ph.D.
Eren Demirhan, Ph.D., has served as Vice President and Head of Biometrics at Nurix since March 2021, leading the Company’s Biostatistics and Clinical Data Science efforts. Dr. Demirhan brings over 17 years of experience in drug pharmaceuticals and biotechnology, championing data-driven drug development ideology and implementation. Prior to joining Nurix, Dr. Demirhan served in a variety of roles at Allogene Therapeutics, Medivation, Onyx Pharmaceuticals, Novartis, Biogen, and GSK. Dr. Demirhan holds a B.A. in Statistics from Middle East Technical University, a Ph.D. in Statistics from North Carolina State University and an M.B.A from Kenan Flagler Business School, University of North Carolina – Chapel Hill.
'